Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Novel Stromal Cell Therapy for Diabetic Kidney Disease (NEPHSTROM Study)

Trial Profile

Novel Stromal Cell Therapy for Diabetic Kidney Disease (NEPHSTROM Study)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Allogeneic bone marrow derived mesenchymal stromal cell therapy Orbsen Therapeutics (Primary)
  • Indications Diabetic nephropathies
  • Focus Adverse reactions; First in man
  • Acronyms NEPHSTROM
  • Most Recent Events

    • 13 Apr 2024 This trial has been completed in Ireland (End Date: 12 Sep 2023), according to European Clinical Trials Database record.
    • 18 Dec 2023 Planned End Date changed from 1 Dec 2023 to 1 Mar 2024.
    • 26 Jan 2023 According to an Orbsen Therapeutics media release, consortium is preparing to submit these first-cohort interim results for publication in a peer-reviewed journal.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top